Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
Dudnik E, Moskovitz M, Daher S, Shamai S, Hanovich E, Grubstein A, Shochat T, Wollner M, Bar J, Merimsky O, Zer A, Goldstein DA, Hammerman A, Cyjon A, Shechtman Y, Abu-Amna M, Flex D, Roisman LC, Peled N; Israel Lung Cancer Group. Dudnik E, et al. Among authors: daher s. Lung Cancer. 2018 Dec;126:217-223. doi: 10.1016/j.lungcan.2017.11.015. Epub 2017 Nov 23. Lung Cancer. 2018. PMID: 29254746
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E, Moskovitz M, Rottenberg Y, Lobachov A, Mandelboim R, Shochat T, Urban D, Wollner M, Nechushtan H, Rotem O, Zer A, Daher S, Bar J; Israel Lung Cancer Group. Dudnik E, et al. Among authors: daher s. Oncoimmunology. 2021 Jan 28;10(1):1865653. doi: 10.1080/2162402X.2020.1865653. Oncoimmunology. 2021. PMID: 33552685 Free PMC article.
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50.
Holtzman L, Moskovitz M, Urban D, Nechushtan H, Keren S, Reinhorn D, Wollner M, Daher S, Rottenberg Y, Rovitzky Y, Shochat T, Bar J, Dudnik E. Holtzman L, et al. Among authors: daher s. Clin Lung Cancer. 2022 Mar;23(2):122-134. doi: 10.1016/j.cllc.2021.12.006. Epub 2021 Dec 24. Clin Lung Cancer. 2022. PMID: 35034862
Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
Saad A, Goldstein J, Appel S, Daher S, Urban D, Onn A, Gantz-Sorotsky H, Lobachov A, Gottfried T, Spieler B, Bar J. Saad A, et al. Among authors: daher s. Thorac Cancer. 2022 Jun;13(12):1763-1771. doi: 10.1111/1759-7714.14452. Epub 2022 May 11. Thorac Cancer. 2022. PMID: 35538909 Free PMC article.
215 results